Study S000417

Clinical Study to Evaluate the Pharmacokinetics and Safety of IBI362 Lyophilized Powder and IBI362 Liquid Formulation in Healthy Chinese Male Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04773977
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 24
Start: 2021-03-03
Primary completion: 2021-03-09
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Overweight/Obesity
Interventions: DRUG:IBI362 liquid formulation; DRUG:IBI362 lyophilized powder
Results posted: FALSE

Registered primary outcomes

Evaluate the PK parameters of IBI362 in healthy Chinese male subjects [From the first dose of study drug until 8 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.